Cargando…

Vasoactive intestinal peptide axis is dysfunctional in patients with Graves’ disease

Vasoactive intestinal peptide (VIP) is a neuropeptide with potent immunoregulatory properties. Reduced serum VIP levels and alterations in VIP receptors/signaling on immune cells have been associated with different inflammatory/autoimmune diseases. However, its role in autoimmune thyroid diseases (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carrión, M., Ramos-Leví, A. M., Seoane, I. V., Martínez-Hernández, R., Serrano-Somavilla, A., Castro, D., Juarranz, Y., González-Álvaro, I., Gomariz, Rosa P., Marazuela, Mónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400547/ https://www.ncbi.nlm.nih.gov/pubmed/32747757 http://dx.doi.org/10.1038/s41598-020-70138-3

Ejemplares similares

The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis
por: Villanueva-Romero, Raúl, et al.
Publicado: (2018)

Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis
por: Martínez, Carmen, et al.
Publicado: (2014)

Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis
por: Seoane, Iria V., et al.
Publicado: (2018)

Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity
por: Seoane, Iria V., et al.
Publicado: (2015)

Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis
por: Juarranz, Yasmina, et al.
Publicado: (2005)

Human CD4(+)CD45RA(+) T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide
por: Villanueva-Romero, Raúl, et al.
Publicado: (2022)

Role of vasoactive intestinal peptide in osteoarthritis
por: Jiang, Wei, et al.
Publicado: (2016)

Vasoactive intestinal peptide secreting tumour: An overview
por: Una Cidon, Esther
Publicado: (2022)

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases
por: Martínez, Carmen, et al.
Publicado: (2019)

Vasoactive intestinal peptide producing pheochromocytoma and intracardiac thrombosis
por: Hermel, Melody, et al.
Publicado: (2021)

Select cognitive deficits in Vasoactive Intestinal Peptide deficient mice
por: Chaudhury, Dipesh, et al.
Publicado: (2008)

Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide
Publicado: (1987)

The effects of vasoactive intestinal peptide on RANKL-induced osteoclast formation
por: Qu, Hongyi, et al.
Publicado: (2021)

Chronic Diarrhea Caused by Vasoactive Intestinal Peptide-Secreting Tumor
por: Belei, Oana, et al.
Publicado: (2023)

Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings
por: Ramos-Leví, Ana M., et al.
Publicado: (2018)

VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts
por: Pérez‐García, Selene, et al.
Publicado: (2016)

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
por: Raderer, M., et al.
Publicado: (1998)

Vasoactive Intestinal Peptide and Its Receptors in Human Ovarian Cortical Follicles
por: Gabbay-Benziv, Rinat, et al.
Publicado: (2012)

Therapeutic effect of vasoactive intestinal peptide on form-deprived amblyopic kittens
por: Li, Bo, et al.
Publicado: (2019)

Vasoactive intestinal peptide regulates ileal goblet cell production in mice
por: Schwerdtfeger, Luke A., et al.
Publicado: (2020)

Hypercalcemia in a Patient Diagnosed with a Vasoactive Intestinal Peptide Tumor
por: Ataallah, Basma, et al.
Publicado: (2020)

Vasoactive intestinal peptide in canine portosystemic shunt in the absence of portal hypertension
por: Isaka, Mitsuhiro, et al.
Publicado: (2021)

Pressure-Dependent Elevation of Vasoactive Intestinal Peptide Level in Chicken Choroid
por: Privalov, Evgeny, et al.
Publicado: (2023)

Mechanism of Immunoregulatory Properties of Vasoactive Intestinal Peptide in the K/BxN Mice Model of Autoimmune Arthritis
por: Leceta, Javier, et al.
Publicado: (2021)

Clostridium difficile suppresses colonic vasoactive intestinal peptide associated with altered motility
por: Nassif, A., et al.
Publicado: (1995)

Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review
por: Wu, Dongmei, et al.
Publicado: (2011)

Role of Vasoactive Intestinal Peptide in Promoting the Pathogenesis of Eosinophilic Esophagitis (EoE)
por: Verma, Alok K., et al.
Publicado: (2017)

Serum substance P and vasoactive intestinal peptide levels in infants with acute intussusception
por: Zhu, Zhen-chuang, et al.
Publicado: (2019)

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system
por: Iwasaki, Mari, et al.
Publicado: (2019)

Vasoactive Intestinal Peptide-Secreting Pancreatic Neuroendocrine Tumor: A Case Report
por: Thivacaren, Sritharan, et al.
Publicado: (2022)

Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature
por: Yee, Shelby K., et al.
Publicado: (2022)

Vasoactive intestinal peptide–VIPR2 signaling regulates tumor cell migration
por: Asano, Satoshi, et al.
Publicado: (2022)

Vasoactive Intestinal Peptide Tumor as the Cause of Persistent Diarrhea: A Diagnostic Challenge
por: Lopes, Sara, et al.
Publicado: (2022)

VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures
por: Lamana, Amalia, et al.
Publicado: (2022)

The Expression of Vasoactive Intestinal Peptide Receptor 1 Is Negatively Modulated by MicroRNA 525-5p
por: Cocco, Elisa, et al.
Publicado: (2010)

Rat Cerebellar Grafts Have (125)I-Vasoactive Intestinal Peptide Binding Sites
por: Moody, T. W., et al.
Publicado: (1992)

In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells
Publicado: (1984)

Vasoactive intestinal peptide inhibits the production of Salmonella-induced inflammatory cytokines by human monocytes
por: Askar, B, et al.
Publicado: (2014)

Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats
por: Xu, Chun-Lan, et al.
Publicado: (2018)

Vasoactive intestinal peptide-expressing interneurons are impaired in a mouse model of Dravet syndrome
por: Goff, Kevin M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6l220ja4s256c6fakdsebo7741